Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Dr. Reddy’s and its subsidiary, Promius Pharma announced the filing of NDA for its migraine candidate DFN-02 with the FDA.
read more
Dr. Reddy’s announced the launch of Ziprasidone Mesylate for Injection, 20 mg (base)/mL Single-dose Vials, the generic equivalent of Geodon.
read more
Monday, December 30, 2019
Dr. Reddy’s announced the launch of Sodium Nitroprusside Injection, 50 mg/2 mL (25 mg/mL) Single-dose Vial, the therapeutic generic equivalent of Nitropress® Injection.
read more
Wednesday, October 10, 2018
Dr. Reddy’s Laboratories has launched Colesevelam HCl Tablets, USP, a therapeutic equivalent generic version of WELCHOL in the United States market approved by the FDA.
read more
Wednesday, November 28, 2018
Dr. Reddy’s announced the launch of Chlorthalidone Tablets USP, 25 mg and 50 mg, a therapeutic equivalent generic version of Hygroton (chlorthalidone) Tablets, approved by the FDA.
read more
Wednesday, December 26, 2018
Dr. Reddy’s announced the launch of Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox, in the U.S. market from the FDA.
read more
Dr. Reddy’s Laboratories has launched Omeprazole and Sodium bicarbonate capsules, 20mg/1100mg and 40mg/1100mg, a therapeutic equivalent generic version of ZEGERID® (omeprazole/sodium bicarbonate) capsules in the United States market, having been ...
read more
Dr. Reddy’s Laboratories has out-licensed the future development, manufacturing, and commercialization rights of DFD-06, a topical high potency steroid, to Encore Dermatology.
read more
Dr. Reddy’s Laboratories has entered into a definitive agreement to acquire a portfolio of 42 approved, non-marketed Abbreviated New Drug Applications (ANDAs) in the U.S.
read more
Dr. Reddy’s Laboratories is voluntarily recalling four lots of Phytonadione Injectable Emulsion USP, 10 mg/mL, Single-Dose Ampules to the hospital level.
read more
Dr. Reddy’s announced the launch of Testosterone Gel 1.62%, a therapeutic equivalent generic version of AndroGel® 1.62%, approved by the FDA.
read more
Dr. Reddy’s Laboratories has announced the launch of Ramelteon Tablets, 8 mg, a therapeutically equivalent generic version of Rozerem® (ramelteon, 8 mg) Tablets.
read more
Wednesday, October 31, 2018
Dr. Reddy’s Laboratories announced the launch of Atomoxetine Capsules, USP, a therapeutic equivalent generic version of Stratter (atomoxetine) Capsules in the United States.
read more
Following a 15-year career with the company, Abhijit Mukherjee, Chief Operating Officer, will retire on March 31, 2018.
read more
Dr. Reddy’s Laboratories has entered into a definitive agreement for the sale of its API manufacturing business unit located in Jeedimetla, Hyderabad, to Therapiva Private, a generics pharmaceutical company.
read more